Norway's Vistin Pharma Q2 revenue falls on currency impact
Norway's Vistin Pharma Q2 revenue falls on currency impact
Overview
Norway pharmaceutical maker's Q2 revenue fell yr/yr due to stronger NOK despite 8% sales volume growth
Q2 EBITDA and net profit declined from prior year, partly due to currency effects
Company paid ordinary cash dividend of NOK 1.0 per share during the quarter
Outlook
Company did not provide specific financial guidance for the current quarter or full year
Result Drivers
CURRENCY IMPACT - Stronger NOK against EUR offset sales volume growth and reduced revenue and EBITDA
SALES VOLUME GROWTH - Co said sales volume rose 8% yr/yr, attributed to expansion into new regions and onboarding new customers
Company press release: ID:nGNECy0Xb
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| NOK 100 mln |
|
Q2 Net Income |
| NOK 14.10 mln |
|
Q2 EBITDA |
| NOK 22 mln |
|
Reuters Recommended Reads
Aug 20 - China's CSPC Pharmaceutical H1 revenue rises on finished drug business growth
Aug 19 - Denmark's Lundbeck Q2 revenue rises 7% driven by Vyepti and Rexulti
Aug 20 - Norway's Kid ASA beats Q2 revenue estimates on strength across segments
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)